Oncostatin M/OSM Antibody (17001)

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

OSM is a cytokine originally isolated from medium conditioned by PMA-treated U-937 human histiocytic leukemia cells based on its ability to inhibit growth of A375 melanoma cells. The human OSM cDNA encodes a 252 amino acid pre-pro-OSM polypeptide with a 25 residue hydrophobic signal peptide and a hydrophilic C-terminal domain that are proteolytically processed to generate the 196 residue mature form of OSM. Although both mature and pro-OSM are equally active in radio-receptor assays, the mature OSM is 5- to 60-fold more active in growth inhibition assays. Thus, proteolytic processing of the pro-OSM peptide may be important in regulating the in vivo activities of OSM.

 

OSM is a pleiotropic cytokine that initiates its biological activities by binding to specific cell surface receptors. The gp130, a signal transducing component ( beta  subunit) of the IL-6, LIF and CNTF receptor complexes, was identified as a low-affinity OSM receptor that does not transduce OSM signals. The low affinity LIF receptor (LIF R, a gp130-related protein) has now been identified to be a component of a high-affinity OSM receptor that will transduce OSM signals. Since OSM is also active on cells that do not express LIF R, a specific OSM receptor that does not involve LIF R must also exist. Besides its growth inhibitory activities on human A375 melanoma and mouse M1 myeloid leukemic cells, as well as on other solid tumor cells, OSM also has growth stimulatory activities on normal fibroblasts, AIDS-Kaposi’s sarcoma cells, and a human erythroleukemia cell line, TF-1. Other OSM-mediated activities reported to date include: stimulation of plasminogen activator activity in cultured bovine aortic endothelial cells; regulation of IL-6 expression in human endothelial cells; and stimulation of LDL uptake and up-regulation of cell surface LDL receptors in HepG2 cells.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 2 confirmed species: Human, Mouse.

We have publications tested in 4 applications: ELISA Development, IHC, Neutralization, Western Blot.

Showing Publications 1 - 10 of 10.

Publications using MAB295	Applications	Species
Sandra Tejedor, Marc Buigues, Hernán González-King, Andreia M. Silva, Nahuel Aquiles García, Niek Dekker et al. Oncostatin M-Enriched Small Extracellular Vesicles Derived from Mesenchymal Stem Cells Prevent Isoproterenol-Induced Fibrosis and Enhance Angiogenesis International Journal of Molecular Sciences 3/30/2023 [PMID: 37047440]
MM Jones, ST Vanyo, W Ibraheem, A Maddi, MB Visser Treponema denticola stimulates Oncostatin M cytokine release and de novo synthesis in neutrophils and macrophages J. Leukoc. Biol., 2020-07-17;0(0):. 2020-07-17 [PMID: 32678942] (IHC, Human)	IHC	Human
C Rolvering, AD Zimmer, A Ginolhac, C Margue, M Kirchmeyer, F Servais, HM Hermanns, S Hergovits, PV Nazarov, N Nicot, S Kreis, S Haan, I Behrmann, C Haan The PD-L1- and IL6-mediated dampening of the IL27/STAT1 anticancer responses are prevented by ?-PD-L1 or ?-IL6 antibodies J. Leukoc. Biol., 2018-07-24;0(0):. 2018-07-24 [PMID: 30040142] (Neutralization, Human)	Neutralization	Human
F Torossian, B Guerton, A Anginot, KA Alexander, C Desterke, S Soave, HW Tseng, N Arouche, L Boutin, I Kulina, M Salga, B Jose, AR Pettit, D Clay, N Rochet, E Vlachos, G Genet, C Debaud, P Denormandi, F Genet, NA Sims, S Banzet, JP Levesque, JJ Lataillade, MC Le Bousse- Macrophage-derived oncostatin M contributes to human and mouse neurogenic heterotopic ossifications JCI Insight, 2017-11-02;2(21):. 2017-11-02 [PMID: 29093266] (Neutralization, Mouse)	Neutralization	Mouse
Su C, Chiang Y, Huang C, Hsu C, Fong Y, Tang C Osteopontin Promotes Oncostatin M Production in Human Osteoblasts: Implication of Rheumatoid Arthritis Therapy. J Immunol, 2015-08-24;195(7):3355-64. 2015-08-24 [PMID: 26304992] (Neutralization, Human)	Neutralization	Human
Mattia Albiero, Nicol Poncina, Stefano Ciciliot, Roberta Cappellari, Lisa Menegazzo, Francesca Ferraro et al. Bone Marrow Macrophages Contribute to Diabetic Stem Cell Mobilopathy by Producing Oncostatin M Diabetes 8/1/2015 [PMID: 25804939]
Nicolaidou V, Wong MM, Redpath AN Monocytes Induce STAT3 Activation in Human Mesenchymal Stem Cells to Promote Osteoblast Formation. PLoS ONE, 2012-07-03;7(7):e39871. 2012-07-03 [PMID: 22802946] (Neutralization, Human)	Neutralization	Human
Morrison C, Mancini S, Cipollone J, Kappelhoff R, Roskelley C, Overall C Microarray and Proteomic Analysis of Breast Cancer Cell and Osteoblast Co-cultures: ROLE OF OSTEOBLAST MATRIX METALLOPROTEINASE (MMP)-13 IN BONE METASTASIS. J. Biol. Chem., 2011-07-22;286(39):34271-85. 2011-07-22 [PMID: 21784845] (Western Blot, Human)	Western Blot	Human
Duluc D, Delneste Y, Tan F, Moles MP, Grimaud L, Lenoir J, Preisser L, Anegon I, Catala L, Ifrah N, Descamps P, Gamelin E, Gascan H, Hebbar M, Jeannin P Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood, 2007-09-11;110(13):4319-30. 2007-09-11 [PMID: 17848619] (Neutralization, Human)	Neutralization	Human
Hurst SM, McLoughlin RM, Monslow J, Owens S, Morgan L, Fuller GM, Topley N, Jones SA Secretion of oncostatin M by infiltrating neutrophils: regulation of IL-6 and chemokine expression in human mesothelial cells. J. Immunol., 2002-11-01;169(9):5244-51. 2002-11-01 [PMID: 12391243] (ELISA Development, Human)	ELISA Development	Human

Array MAB295

• Oncostatin M/OSM Antibodies
• Oncostatin M/OSM ELISA Kit
• Oncostatin M/OSM Lysate
• Oncostatin M/OSM Proteins
• Oncostatin M/OSM ELISAs
• Oncostatin M/OSM Proteins and Enzymes